Cipla is reportedly planning to re-start supplying anti-HIV drugs to the National Aids Control Organisation (Naco) in the next two months.
The Mumbai-based drug company had, during the second half of last year, stopped bidding for Naco tenders. The company had participated in the Naco’s paediatric tenders, which were being evaluated.
Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1674.25 |
| Dr. Reddys Lab | 1235.85 |
| Cipla | 1236.25 |
| Zydus Lifesciences | 941.20 |
| Lupin | 2336.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: